Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agios just another pump and dump??
Be careful investors, do your research, take a closer look. Agios is a company involved in developing biologic drugs.....the CSO of Agios is a chemist..... the person holding such a position is supposed to be a biologist, someone with a background in biology, not small molecule drugs.
The truth is the CSO has no experience in his background to make him suitable for such a position.....
Entresto will flop
All they've done is capitalize on the benefits of switching someone with CHF and COPD from and ACE inhibitor to an ARB, any ARB.
These days pretty much everyone with CHF also has COPD.
They are using a massive marketing campaign with many TV commercials to try and convince people that Entresto is something new when it's mainly comprised of the same drug (valsartan) that was their once big time seller they called DIOVAN, they recently lost patent protection on.
Their trial did not include a true head to head comparison of valsartan vs valsartan/sacubitril.
They try and convince people that using an ARB instead of an ACE inhibitor for CHF is something new, ARB's have been around for years and there are many examples from many companies.
Doctors and insurance companies will soon get wise to this and Entresto sales will plummet.
Never before in history has a pharma tried such an attempt at repackaging and re-patenting a drug that they lost patent protection on in this manner, people will catch on eventually.
forgot to mention only one year at some place called theriac, it's ridiculous.
technical investors could care less, but anyone doing research on companies really needs to take a close look at who the so called chief scientific officer is.
We'll take a look at the history of some of the other trough feeders later.
Don't say you weren't warned about this place.
Just read this garbage they post about noronha, the quote unquote "chief scientific officer"
The below bio was taken from the clearside website sept 30, 2018
His track record is a joke, previous posts outlined the fiasco at Targegen where they burned Sanofi and his being drummed out of a device company prior and then what.....
a couple years at Alcon
a year at a place called sucampo
Then a few years at this clearside place
This is tantamount to wirefraud against investors, this guy isn't qualified to lead any scientific effort. Could you get a job with a resume like that!?! a year here, a couple years there all over the place. The truth is Clearside is a pump and dump just take a look at how many executives they have feeding at the trough, and all for what? There's hardly anything going on at this place.
This is his "bio" from Sept 30, 2018....these people have no shame, they think investors are morons obviously.....
Dr. Noronha was promoted to Chief Scientific Officer in August 2016 after having served as our Executive Vice President, Research and Development since August 2013. Dr. Noronha plays a critical role in all strategic, developmental and regulatory efforts at Clearside. From 2012 to 2013, he served as Vice President, Research and Development, at Sucampo Pharma Americas, LLC. From 2011 to 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development in oncology. From 2008 to 2011, Dr. Noronha was Global Project Lead for developmental efforts in retinal diseases at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions with increasing levels of leadership and responsibility at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Dr. Noronha received his education and training in Chicago and Irvine.
After all these years arqule executives are still feeding at the trough after suckering investors into believing they had robots doing chemistry.
The VP of chemistry was so computer illiterate he didn't even have one on his desk, his secretary had to print him emails and hand them to him.
He would coach chemists to lie to prospective clients that chemistry they had painstakingly done by hand was done with robotics. Big deal, they took standard industry fluid handlers used in biology and used them to dispense fluids. It was so comical, they would spend more time setting the thing up than it would take to just do it by hand.
All they managed to do was get a cash for compound deal from Pfizer who had many such deals with other companies. Once they gave up on that ploy hardly any of the senior chemists there could get anyone to give them a job.
For all these years the shareholder was then stuck with a group of mediocre people no one would hire supposedly looking for cancer cures making reams of useless compounds.
Still to this day shareholders are stuck providing this group of clowns with cushy six figure jobs.
What an industry, small wonder VC's don't buy into the BS anymore.
Ulrich/Nohura spin at Targegen, end result BURN on Sanofi......
bout how TargeGen was able to discover its lead drug candidate, TG101348, in-house, and was able to bring it into clinical trials in 18 months with the help of a China-based contract research organization, WuXi Pharmatech. Two years later, the company had proven the concept with data from a mid-stage clinical trial that paved the way for today’s acquisition. Now it will be up to Sanofi to see just how lucrative this drug might be for investors, and valuable it may be for patients. Incyte may reach the market first in this category, Royston says, but he says the TargeGen drug could be the ultimate winner.
Nohura and Ulrich burned Sanofi at Targegen big time and White is trying to do the same to you.
Nohura isn't even remotely qualified, he was drummed out of a device mfg and no one else would hire him in San Diego. He would be cutoff during interviews and kicked out of the building. Not even his own supervisor at Targegen wanted him, Ulrich wanted a loudmouth to help him spin their crap and that's exactly what they had.
Sanofi is trying to take legal action for what was done to them.
Pay attention investors, do your research, there are SO MANY talented chemists available from the pharma downturn, why would White pick a no talent, no track record hack like Nohura.
You guys all cry the blues when you get burned by biotech pump and dumps, do a little research on who is installed in key scientific positions.
I just got off the phone with him
Every time I asked Menon when we were going to interact with Danishefsky he would say "oh I just got off the phone with him"
These people actually think they're believable, bloody sociopaths.
The only reason I went to work there was because they said Danishefsky was on their SAB, what a pile of lying BS
Insiders chime in NOW
Money laundering for sure
hope to hell the feds figure out what menon is up to with his "King" from his home town in India.
Ask Boston area people about Menon
Ask around Boston about Menon, he has quite the reputation.....
Ever talk to Menon, LOL!!!
Have any of you ever sat down and had a conversation with this character?
Why did they change the company name???
IPIX is only a reasonable facsimile of a pharmaceutical company.
As with most pump and dump biotechs, they put a lot of time into making things "just good enough".
When Menon was told by his chemist that his suggestion of Kevetrin being a "kinase inhibitor" with activity about 5 orders of magnitude less than industry recognized standards, his reply was "doesn't matter it's just academic"
Maybe you guys don't understand the gravity of a few points here because you aren't scientists.
When a character like Menon goes around telling everyone he went to Harvard when he didn't, when he says a world renowned chemist is on his SAB when he isn't, that's a big thing. It immediately removes all credibility from that point on.
It doesn't matter how far back in the past it happened.
What are they saying now, that their compound is effective against MRSA, OH ok, that's good one, do you realize how many reputable companies and scientists are working on such things???
In the end people attach too much gravity to phase I, II trials. This is something you can essentially just buy as long as you have something that doesn't make the rats drop dead.
As has been mentioned before, when diverse analogs of Kevetrin were made, they all showed the same kind of macro effects. This is a test in medicinal chemistry. If you make a minor change to a molecule, if there isn't a corresponding change in activity then there isn't ANY specific activity.
Regardless a letter has been sent to the judge in the class action suit pointing out a few things about wire fraud etc. and making false statements to the FDA during submissions to them.
Leo Lies about Menon "clerical mistake" regarding false statements about qualifications.
Menon unabashedly promoted himself as having a PhD in pharmacology from Harvard. It was only after someone actually called Harvard and they confirmed he never even went there that they were forced to change this lie.
Menon was nothing more than a post doc making subsistence level wages at Dana Farber, hardly a notable researcher. These jobs are a dime a dozen and people take them because no one will give them a real job.
To this day no one has ever been able to confirm that a world renowned chemist from Columbia university ever had anything to do with cellceutix/innovation.
Why the name change anyway?
Cellceutix/innovation wire fraud
If you lie about your credentials, as a founding scientist, on a website for a publicly traded company, that's wire fraud
facts about Cellceutix/innovation pharmaceuticals.
At first menon claimed he had a PhD in pharmacology from Harvard, he even stated this in his bio on the company web page.
it was not until after someone contacted Harvard and verifying he was never a student there, that they finally changed the bio.
The truth is Menon is a veterinarian from the carribean. He worked in the animal testing facilities at a pharma, thats it.
There is no basis to "kevetrin" it's ridiculous, people fail to differentiate between "orphan drug" and "orphan drug development", they capitalize on this. At first it was a kinase inhibitor with only millimolar activity then it induces activation of the guardian of the genome, where do they come up with this stuff, its embarrassing. There is no one with any real experience involved with the science.
They made claims a renowned Columbia chemist was on their SAB, when he was asked about Cellceutix, he said he didn't even know them.
He would claim elderly professors long since retired to be on their SAB as well
The FDA shouldn't allow people that lie about their credentials to play the system.
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
Entresto is nothing more than an attempt by Novartis to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
There are other things to watch for with regards to Novartis integrity, such as making facilities managers from a failed pump and dump like ArQule into an "automation guru". There are so many highly qualified people in the industry to choose from for such roles yet they hired a "facilities manager", how embarrassing, these pharmaceutical companies don't even make an honest effort anymore.
Kard Scientific was a company owned by Krishna Menon and operated out of the exact same suite at Cummings Center that Cellceutix (now Innovation Pharmaceuticals) did. Most of the scientists worked for Kard Scientific. Cellceutix employees sat in the front offices.
As a chemist that worked for Kard Scientific, a ghost company setup by Krishna Menon to do "research" for Cellceutix, which has been renamed Innovation Pharmaceuticals, I feel compelled to inform people of a few facts.
I do not hold any stock in this "company" nor have I ever.
Krishna Menon claimed that he had a PhD in pharmacology from Harvard University. I contacted Harvard and they confirmed that he DID NOT HAVE A PhD IN PHARMACALOGY FROM THEIR INSTITUTION.
It was only after exposing this fraud that cellceutix was forced to retract this claim. The applications to the Federal Government for grants were made with this fraudulent misrepresentation of his academic qualifications.
The truth is that Krishna Menon is a veterinarian from the Caribbean.
Krishn Menon, and Cellceutix claimed that a world renowned chemistry professor from Columbia University, one Samuel J. Danishefsky, was a member of their SAB (scientific advisory board). The truth is he doesn't even know Krishna Menon. I challenge anyone to prove there was ever a connection.